Skip to main content

REVIEW article

Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1422591
This article is part of the Research Topic Potency Assays for Use in Manufacturing Cellular Immunotherapies View all articles

Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention

Provisionally accepted
Jingxian Li Jingxian Li 1Huiguang Chen Huiguang Chen 1Chaoping Xu Chaoping Xu 2*Meng Ci Hu Meng Ci Hu 2Jiangping Li Jiangping Li 2*Wei Chang Wei Chang 2*
  • 1 Wuhan University of Science and Technology, Wuhan, China
  • 2 Wuhan Puren Hospital, Wuhan, Hubei Province, China

The final, formatted version of the article will be published soon.

    Malignant tumors of the hematologic system have a high degree of malignancy and high mortality rates. Chimeric antigen receptor T cell (CAR-T) therapy has become an important option for patients with relapsed/refractory tumors, showing astonishing therapeutic effects and thus, it has brought new hope to the treatment of malignant tumors of the hematologic system. Despite the significant therapeutic effects of CAR-T, its toxic reactions, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), cannot be ignored since they can cause damage to multiple systems, including the cardiovascular system. We summarize biomarkers related to prediction, diagnosis, therapeutic efficacy, and prognosis, further exploring potential monitoring indicators for toxicity prevention. This review aims to summarize the effects of CAR-T therapy on the cardiovascular, hematologic, and nervous systems, as well as potential biomarkers, and to explore potential monitoring indicators for preventing toxicity, thereby providing references for clinical regulation and assessment of therapeutic effects.

    Keywords: Chimeric antigen receptor T cell1, hematologic malignancy2, adverse events3, Biomarkers4, Toxicity5, monitoring indicators6

    Received: 24 Apr 2024; Accepted: 08 Aug 2024.

    Copyright: © 2024 Li, Chen, Xu, Hu, Li and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Chaoping Xu, Wuhan Puren Hospital, Wuhan, Hubei Province, China
    Jiangping Li, Wuhan Puren Hospital, Wuhan, Hubei Province, China
    Wei Chang, Wuhan Puren Hospital, Wuhan, Hubei Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.